Cargando…
Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system. Relapse and incomplete recovery from relapse are common in NMOSD. Most patients with NMOSD have IgG to aquaporin-4 (AQP4-IgG). New biological agents for AQP4-IgG-seropositive NMOSD, such as sat...
Autores principales: | Li, Xiaojing, Wu, Wenlin, Zeng, Yiru, Wu, Wenxiao, Hou, Chi, Zhu, Haixia, Liao, Yinting, Tian, Yang, Chen, Zongzong, Peng, Bingwei, Chen, Wen-Xiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616785/ https://www.ncbi.nlm.nih.gov/pubmed/37915570 http://dx.doi.org/10.3389/fimmu.2023.1257955 |
Ejemplares similares
-
Satralizumab for neuromyelitis optica spectrum disorder
Publicado: (2021) -
Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
por: Uzawa, Akiyuki, et al.
Publicado: (2022) -
Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
por: Kleiter, Ingo, et al.
Publicado: (2022) -
Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020) -
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab
por: Bennett, Jeffrey L., et al.
Publicado: (2023)